Guðmundur Fertram Sigurjónsson, an inventor from a tiny fishing village in Iceland, has turned the skin of North Atlantic cod into a medical product that can stay on a wound and be absorbed as the body heals. His company Kerecis markets the material as a bio‑compatible dressing that integrates with human tissue, potentially reducing the need for frequent changes that can damage fragile new skin.

Traditional wound dressings, including those made from pig skin, must be removed and replaced, a process that can disrupt the healing process. Cod skin, by contrast, remains in place; cells grow into it and the material is gradually broken down and replaced by the patient's own tissue.

Scientific evidence and remaining questions

More than a hundred studies have examined fish‑skin grafts, but the most robust data come from a randomised trial involving 255 patients with deep diabetic foot ulcers. Funded in part by Kerecis, the study reported that after 16 weeks 44% of wounds treated with cod skin had healed, versus 26% under standard care. At 24 weeks the figures rose to 55% and 38% respectively.

Professor Dimitri Beeckman of Örebro and Ghent Universities cautioned that while the results are promising, the evidence base is still limited. "Direct comparisons with porcine material have been small and often involved experimental wounds on healthy volunteers," he said, underscoring the need for larger, independent trials.

Advantages and practical use

Cod skin's biological distance from humans means the pathogens that thrive in cold‑water fish are unlikely to survive in the warmer human body, reducing the risk of disease transmission. Unlike mammalian grafts, which require harsh sterilisation, the fish product can be stored at room temperature and has a long shelf life, making it attractive for use in remote or conflict‑affected areas.

Kerecis has supplied the material to hospitals and humanitarian groups, including donations for patients injured in Ukraine. The lightweight, durable grafts can be shipped and stored without refrigeration, a logistical benefit in war zones where medical supplies are scarce.

Cost considerations and future outlook

Despite the clinical promise, cod‑skin grafts are generally more expensive than conventional dressings, and reimbursement policies vary across European health systems. Beeckman noted that comprehensive health‑economic analyses are still lacking, and that cost‑effectiveness will be a decisive factor for wider adoption.

Sigurjónsson says Kerecis has already treated hundreds of thousands of patients worldwide, but he acknowledges that broader uptake will depend on further independent research, real‑world evidence, and clearer pricing structures.

The debate over fish‑skin grafts reflects a broader tension in European health policy: balancing innovative, potentially more effective treatments against the fiscal pressures facing public health systems. As more data emerge, clinicians and policymakers will need to decide whether the added expense translates into enough benefit to justify routine use.